Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans

Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast

(2010) T Karonen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Human CYP2C8: Structure, Substrate Specificity, Inhibitor Selectivity, Inducers and Polymorphisms

(2010) Xin-Sheng Lai et al.   CURRENT DRUG METABOLISM

Benzylic Oxidation of Gemfibrozil-1-O-β-Glucuronide by P450 2C8 Leads to Heme Alkylation and Irreversible Inhibition

(2009) Brian R. Baer et al.   CHEMICAL RESEARCH IN TOXICOLOGY

CYP2C8 Activity Recovers within 96 Hours after Gemfibrozil Dosing: Estimation of CYP2C8 Half-Life Using Repaglinide as an in Vivo Probe

(2009) J. T. Backman et al.   DRUG METABOLISM AND DISPOSITION

The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America

(2009) S. W. Grimm et al.   DRUG METABOLISM AND DISPOSITION

Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies

(2009) Elizabeth B Daily et al.   PHARMACOGENOMICS

The effect ofSLCO1B1polymorphism on repaglinide pharmacokinetics persists over a wide dose range

(2008) Annikka Kalliokoski et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The Effect of Gemfibrozil on Repaglinide Pharmacokinetics Persists for at Least 12 h After the Dose: Evidence for Mechanism-based Inhibition of CYP2C8 In Vivo

(2008) A Tornio et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effects of Gemfibrozil and Atorvastatin on the Pharmacokinetics of Repaglinide in Relation to SLCO1B1 Polymorphism

(2008) A Kalliokoski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Cytochrome P450 Turnover: Regulation of Synthesis and Degradation, Methods for Determining Rates, and Implications for the Prediction of Drug Interactions

(2008) Jiansong Yang et al.   CURRENT DRUG METABOLISM

Determination of mRNA Expression of Human UDP-Glucuronosyltransferases and Application for Localization in Various Human Tissues by Real-Time Reverse Transcriptase-Polymerase Chain Reaction

(2008) S. Ohno et al.   DRUG METABOLISM AND DISPOSITION

Expression of UGT1A and UGT2B mRNA in Human Normal Tissues and Various Cell Lines

(2008) A. Nakamura et al.   DRUG METABOLISM AND DISPOSITION

Mechanism-based inhibition of cytochrome P450 enzymes: An evaluation of early decision making in vitro approaches and drug–drug interaction prediction methods

(2008) Kenneth H. Grime et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Different Effects ofSLCO1B1Polymorphism on the Pharmacokinetics and Pharmacodynamics of Repaglinide and Nateglinide

(2008) Annikka Kalliokoski et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide

(2008) Annikka Kalliokoski et al.   Pharmacogenetics and Genomics